Schumann A, Fiedler M, Dahmen U, Grosse-Wilde H, Roggendorf M, Lindemann M
Institut für Virologie, and Institut für Immunologie, Universitätsklinikum Essen, Essen, Germany.
J Viral Hepat. 2007 Aug;14(8):592-8. doi: 10.1111/j.1365-2893.2007.00848.x.
Liver transplantation is often the ultimate option of therapy for chronically hepatitis B virus (HBV) infected patients. Adoptive transfer of HBV immunity with the liver after vaccination of living liver donors (LLD) could be a new approach to prevent reinfection in the recipients. The time to achieve HBV immunity in LLD is usually short (1-2 months). Therefore, we established a short time immunization protocol (four injections in 2 weeks intervals) using Hepimmune, a recombinant vaccine that contains the L, M and S proteins of HBV. We examined cellular and humoral immune responses after immunization with Hepimmune and compared its immunogenicity to that of a standard HBV vaccine containing only the S protein (HBVAXPRO). Cellular immunity was measured by interferon (IFN)-gamma ELISpot and proliferation assay. HBV-specific T cells were detectable in the Hepimmune group after the second and in the standard group after the third vaccination. IFN-gamma production of T cells was significantly higher (P < 0.001) after the third vaccination with Hepimmune. Proliferative responses were also significantly (P < 0.01) higher in the Hepimmune group after the second to fourth vaccination. The humoral immune response could already be detected after the first immunization in nine of 15 Hepimmune vaccinated test persons while it was only observed in one of 15 probands of the later group. Titres differed significantly (P < 0.01) following all four vaccinations. Thus, Hepimmune appears to be a good candidate for short time immunization protocols.
肝移植通常是慢性乙型肝炎病毒（HBV）感染患者的最终治疗选择。在活体肝供者（LLD）接种疫苗后，通过肝脏进行HBV免疫的过继性转移可能是预防受者再感染的一种新方法。LLD获得HBV免疫的时间通常较短（1 - 2个月）。因此，我们使用Hepimmune（一种包含HBV的L、M和S蛋白的重组疫苗）建立了一种短时间免疫方案（每2周注射4次）。我们检测了用Hepimmune免疫后的细胞和体液免疫反应，并将其免疫原性与仅含S蛋白的标准HBV疫苗（HBVAXPRO）进行比较。通过干扰素（IFN）-γ ELISpot和增殖试验测量细胞免疫。在第二次接种后，Hepimmune组可检测到HBV特异性T细胞，而标准组在第三次接种后可检测到。用Hepimmune进行第三次接种后，T细胞的IFN-γ产生显著更高（P < 0.001）。在第二次至第四次接种后，Hepimmune组的增殖反应也显著更高（P < 0.01）。在15名接种Hepimmune的受试人员中，有9人在首次免疫后即可检测到体液免疫反应，而在标准组的15名受试者中，只有1人观察到这种情况。在所有四次接种后，抗体滴度差异显著（P < 0.01）。因此，Hepimmune似乎是短时间免疫方案的一个良好候选者。
